Samsung Medical Center
Seoul, 135-710, South Korea
NCT Number: NCT01043250
In this study, we are going to investigate quantitative and qualitative natures of appetite and eating-behavior changes induced by atypical antipsychotics, i.e., risperidone, olanzapine and aripiprazole, in schizophrenia patients.
Looking for future studies?
Notify Me19 year–59 year
All sexes
Observational
Seoul, 135-710, South Korea
This is an observational study. 2 Self-report questionnaires assessing changes of appetite and eating behaviors after medication are applied to patients who have been receiving one of the three atypical antipsychotics. We are going to compare changes of appetite and eating behaviors after medication between three atypical antipsychotics and investigate the association between changes of appetite and eating behaviors and changes of weight after medication.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: between 2 and 24months after starting medication
Time frame: between 2 and 24 months after starting medication
Looking for future studies?
Notify MeSamsung Medical Center
Other
Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients: Analysis for Three Drugs, Olanzapine, Risperidone, and Aripiprazole, Known to Induce Different Degrees of Weight Gain
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00942981
Mental Disorders, Psychotic Disorders
Bethesda, Maryland, United States
View Trial DetailsNCT00001486
Behavior, Behavioral Symptoms
Bethesda, Maryland, United States
View Trial DetailsNCT03261557
Mental Disorders, Psychosis NOS
Barcelona, Catalonia, Spain
View Trial DetailsNCT07374588
Behavior, Bipolar Disorder With Psychotic Features
Sivas, Turkey (Türkiye)
View Trial Details